Semaglutide vs Tirzepatide: Complete Comparison

Side-by-Side Comparison Table

Weight Loss Efficacy: Semaglutide vs Tirzepatide

In their respective pivotal trials, Semaglutide achieved a mean weight loss of 14.9% (STEP-1) while Tirzepatide achieved 22.5% (SURMOUNT-1). This 7.6 percentage point difference represents a clinically meaningful gap, though direct head-to-head trial data between these specific agents may be limited.

Important caveat: These trials enrolled different populations (different BMI criteria, T2D vs non-diabetic, different geographies) and used different primary endpoints. Direct comparisons should be interpreted with caution.

Mechanism: How They Work Differently

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a GIP/GLP-1 dual receptor agonist. The dual receptor activation of Tirzepatide targeting both GIP and GLP-1 receptors is hypothesized to produce additive or synergistic metabolic effects beyond GLP-1 agonism alone.

Side Effects

Both Semaglutide and Tirzepatide share a similar GI side effect profile. Common side effects for both include: constipation, diarrhea, fatigue, injection-site reaction. These are typically most pronounced during dose escalation and improve with time.

Semaglutide-specific: headache. Tirzepatide-specific: abdominal pain

Cost Comparison

Cash pay prices vary significantly: Semaglutide lists at approximately $1349/month vs Tirzepatide at $1086/month. Both require prior authorization through most commercial insurers.

Which Is Right for You? Decision Guide

Bottom line: The choice between Semaglutide and Tirzepatide is best made with your prescribing clinician, accounting for your specific medical history, insurance coverage, prior treatment response, and metabolic goals. Neither medication is universally superior for all patients.

SURMOUNT-5: The Direct Head-to-Head Trial

Until 2025, semaglutide and tirzepatide had never been compared in a single randomized trial. That changed with SURMOUNT-5 (Aronne et al., NEJM 2025), a phase 3b open-label randomized controlled trial enrolling 751 adults with obesity (BMI ≥30) or overweight with a weight-related comorbidity, none with type 2 diabetes. Participants received the maximum tolerated dose of tirzepatide (10 or 15 mg) or the maximum tolerated dose of semaglutide (1.7 or 2.4 mg) weekly for 72 weeks.

At week 72, tirzepatide produced a mean body weight reduction of −20.2% (95% CI: −21.4 to −19.1) versus −13.7% (95% CI: −14.9 to −12.6) for semaglutide (p<0.001) — a 47% greater relative weight reduction. In absolute terms, the tirzepatide group lost roughly 22.8 kg (50 lbs) compared to 15.0 kg (33 lbs) for semaglutide. Tirzepatide was superior at every pre-specified weight-loss milestone threshold: at least 20% weight loss was achieved by 48.4% of tirzepatide participants vs. 27.3% on semaglutide; at least 30% weight loss (an outcome historically confined to bariatric surgery) was achieved by 19.7% on tirzepatide vs. just 6.9% on semaglutide.

Two important caveats: SURMOUNT-5 was open-label (neither patients nor investigators were blinded) and was funded by Eli Lilly. The trial was not powered to formally compare safety profiles. These limitations do not invalidate the efficacy findings, but they should be weighed alongside the data.

STEP 1 Semaglutide Data

The foundational evidence for semaglutide in obesity is STEP 1 (Wilding et al., NEJM 2021), a phase 3 double-blind placebo-controlled trial enrolling 1,961 adults without type 2 diabetes at 129 sites across 16 countries. Participants were randomized 2:1 to semaglutide 2.4 mg subcutaneously once weekly or placebo alongside lifestyle counseling for 68 weeks.

At 68 weeks, semaglutide produced a mean body weight reduction of −14.9% versus −2.4% for placebo (treatment difference −12.4 percentage points; 95% CI: −13.4 to −11.5; p<0.001). The milestone breakdown is clinically important: 86.4% of semaglutide participants lost at least 5% of body weight vs. 31.5% on placebo; 69.1% lost at least 10% vs. 12.0%; 50.5% lost at least 15% vs. 4.9%; and approximately 32% achieved at least 20% weight loss vs. roughly 2% on placebo. For context, 15% weight loss was previously achievable only through bariatric surgical procedures.

The broader STEP program (STEP 1, 3, 4, 8) in non-diabetic participants produced mean weight loss ranging from 14.9% to 17.4% across 68-week trials. The STEP 5 two-year trial (Garvey et al., Nature Medicine 2022) found a mean 15.2% weight reduction at 104 weeks, confirming that weight loss is maintained with continued therapy. These data supported FDA approval of Wegovy in June 2021.

SURMOUNT-1 Tirzepatide Data

SURMOUNT-1 (Jastreboff et al., NEJM 2022) was a phase 3 double-blind placebo-controlled trial enrolling 2,539 adults without type 2 diabetes at 119 sites across nine countries. Participants were randomized to tirzepatide 5 mg, 10 mg, or 15 mg, or placebo, weekly for 72 weeks alongside lifestyle intervention.

The dose-response relationship was clinically meaningful. At 72 weeks, mean body weight change was −15.0% for 5 mg, −19.5% for 10 mg, and −20.9% for 15 mg, compared to −3.1% for placebo. The largest incremental gain occurred between 5 mg and 10 mg (~4.5 percentage points); the 10-to-15 mg step added only ~1.5 additional percentage points, suggesting efficacy approaches saturation near the 15 mg ceiling dose. At 15 mg, 90.9% of participants lost at least 5%, 56.7% lost at least 20%, and roughly 15% achieved at least 30% weight loss. Three-year extension data showed maintained weight loss of −19.7% at week 176 for the 15 mg group, with a 96% reduction in new-onset type 2 diabetes compared to the placebo arm.

SURMOUNT-1 established tirzepatide as the most effective FDA-approved pharmacotherapy for obesity at publication. It directly supported FDA approval of Zepbound (tirzepatide for weight management) in November 2023.

Mechanism Differences That Matter

Semaglutide is a selective GLP-1 receptor agonist. It activates GLP-1 receptors in the hypothalamus and brainstem to suppress appetite, slows gastric emptying to prolong satiety, and stimulates glucose-dependent insulin secretion while suppressing glucagon. These pathways are well-characterized and explain its robust efficacy.

Tirzepatide adds a second dimension: it is a co-agonist at both the GIP receptor (GIPR) and the GLP-1 receptor, with its molecular structure based primarily on native GIP. The additional GIP receptor activation contributes in at least four ways. First, GIP is the other major incretin hormone (secreted by duodenal K-cells), and dual GIPR/GLP-1R activation produces additive or synergistic insulinotropic effects beyond GLP-1 agonism alone (Thomas et al., J Clin Endocrinol Metab 2021). Second, GIP receptors are expressed directly on adipocytes, where GIPR agonism increases lipolysis, elevates adiponectin, and provides insulin-sensitizing effects independent of weight loss. Third, preclinical data show tirzepatide promotes branched-chain amino acid catabolism in brown adipose tissue, activating thermogenic-like pathways not observed with pure GLP-1 agonists (Gillum et al., Molecular Metabolism 2022). Fourth, structural analyses show tirzepatide exhibits biased signaling at the GLP-1R favoring the cyclic AMP pathway, with less receptor desensitization than semaglutide (Coskun et al., PNAS 2022).

The net result: tirzepatide acts on more metabolic pathways than a pure GLP-1 agonist, likely explaining its greater weight-loss ceiling in head-to-head data.

GI Side Effect Comparison: Head-to-Head Numbers

SURMOUNT-5 provides the only randomized head-to-head gastrointestinal safety comparison. The data from Aronne et al. (NEJM 2025) show profiles that are broadly similar but with notable differences in tolerability-related dropout:

The most clinically meaningful finding is tolerability-driven dropout: twice as many semaglutide patients quit due to GI adverse events (5.6% vs. 2.7%). Nausea rates were nearly identical. Vomiting was notably more common with semaglutide (21.3% vs. 15.0%). Investigators have hypothesized that GIP co-agonism may attenuate the GLP-1-driven nausea/vomiting burden, though this is not definitively established. Both drugs carry identical class-level FDA warnings: thyroid C-cell tumor risk (contraindicated in MTC/MEN2 history), acute pancreatitis caution, and gallbladder disease risk. A 2025 meta-analysis found semaglutide increases cholelithiasis risk ~2.6-fold vs. controls; tirzepatide showed no significant biliary risk in the same analysis (Annals of Saudi Medicine 2025).

Cardiovascular Outcomes Evidence

As of mid-2026, semaglutide holds a meaningful advantage in cardiovascular outcomes evidence. In the diabetic population, SUSTAIN-6 (Marso et al., NEJM 2016) enrolled 3,297 adults with type 2 diabetes at high cardiovascular risk and found that semaglutide reduced the composite of cardiovascular death, nonfatal MI, or nonfatal stroke by 26% vs. placebo (HR 0.74; 95% CI 0.58–0.95), driven largely by a 39% reduction in nonfatal stroke.

More consequentially, the SELECT trial (Lincoff et al., NEJM 2023) enrolled 17,604 adults with obesity and established cardiovascular disease but without diabetes. After a mean follow-up of nearly 40 months, semaglutide reduced the primary MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) by 20% vs. placebo (HR 0.80; 95% CI 0.72–0.90; p<0.001). This landmark trial led the FDA to expand Wegovy's label in March 2024 to include reduction of serious cardiovascular events — making semaglutide the first obesity pharmacotherapy with a proven, FDA-labeled cardiovascular benefit in non-diabetic patients.

For tirzepatide, SURPASS-CVOT (NEJM 2025) compared tirzepatide vs. dulaglutide (a GLP-1 RA with established cardiovascular benefit) in adults with type 2 diabetes and established ASCVD over four years. Tirzepatide was noninferior to dulaglutide for MACE (HR 0.92; 95.3% CI 0.83–1.01; p=0.003 for non-inferiority) but did not achieve superiority. It did show a nominally significant 16% reduction in all-cause mortality. SURMOUNT-MMO — the tirzepatide MACE outcomes trial equivalent to SELECT, in non-diabetic patients with obesity and established CVD — remains ongoing as of mid-2026 (NCT05556512). Until those results publish, tirzepatide does not carry an FDA-approved cardiovascular risk reduction indication in non-diabetic obesity.

Which Drug for Which Patient?

The following profiles reflect the weight of clinical evidence as of June 2026. Individual decisions depend on patient-specific factors, formulary access, and current clinical guidelines.

Non-diabetic adult, primary goal is maximum weight loss, no established CVD: Evidence favors tirzepatide (Zepbound). SURMOUNT-5 demonstrated 20.2% mean weight loss vs. 13.7% for semaglutide, with superiority at every weight-loss milestone. Without established CVD, semaglutide's SELECT-based cardiovascular indication advantage does not apply. Both the EASO (October 2025) and ACC (June 2025) support tirzepatide as the preferred efficacy choice here. Cost and formulary coverage may override the efficacy argument.

Patient with established CVD (prior MI, stroke, symptomatic PAD) and obesity, with or without type 2 diabetes: Evidence favors semaglutide (Wegovy if non-diabetic; Ozempic if diabetic). Semaglutide is the only obesity pharmacotherapy with an FDA-approved cardiovascular risk reduction indication in non-diabetic patients (based on SELECT). For diabetic patients with ASCVD, SUSTAIN-6 also supports semaglutide; SURPASS-CVOT established tirzepatide as non-inferior to dulaglutide but the SELECT-equivalent MACE data for tirzepatide in non-diabetic obesity have not yet reported.

Type 2 diabetic without established CVD, elevated HbA1c (≥8%), BMI ≥30: Evidence favors tirzepatide (Mounjaro). SURPASS-2 showed tirzepatide 15 mg reduced HbA1c by 2.30% vs. 1.86% for semaglutide 1 mg over 40 weeks. Tirzepatide's dual mechanism provides superior glycemic and weight outcomes in this population.

Cost-sensitive patient without insurance: At full maintenance dosing, Wegovy through NovoCare is $349/month vs. Zepbound through LillyDirect at $449/month. Semaglutide is cheaper out-of-pocket for self-pay patients; tirzepatide costs more but may deliver greater weight loss per dollar spent for some patients. Medicare beneficiaries qualifying for the GLP-1 Bridge program (July 2026–December 2027) can access both at approximately $50/month.

Patient with gastroparesis or significant GI motility concerns: Extreme caution is warranted with both drugs. A large real-world cohort (DDW 2026) found tirzepatide was associated with a lower rate of gastroparesis than semaglutide (0.2% vs. 0.5% in propensity-matched data), but both carry similar FDA-label warnings. If either is used, slow titration and close clinical monitoring are essential.